Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Canada; Department of Pharmacology & Toxicology, University of Toronto, Toronto, Canada; Canadian Partnership for Stroke Recovery, Sunnybrook Research Institute, Toronto, Canada; University Health Network Toronto Rehabilitation Institute, Toronto, Canada.
Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Canada; University Health Network Toronto Rehabilitation Institute, Toronto, Canada; Neuropsychopharmacology Research Group, Sunnybrook Research Institute, Toronto, Ontario, Canada.
J Diabetes Complications. 2019 May;33(5):390-397. doi: 10.1016/j.jdiacomp.2019.01.003. Epub 2019 Jan 17.
Lower serum concentrations of the osteoblast-derived protein, osteocalcin, have been associated with poorer glycemic control, insulin resistance and atherosclerosis, and with the development of type 2 diabetes (T2DM).
This study compares concentrations of two physiological forms of osteocalcin, carboxylated (cOCN) and uncarboxylated (unOCN), between participants with T2DM (n = 20) and age-, gender- and body mass index (BMI)-matched participants without T2DM (n = 40) among patients with coronary artery disease (CAD), and it explores relationships between osteocalcin concentrations and cardiovascular risk factors.
Concentrations of unOCN (2.71 ± 1.86 vs. 4.70 ± 2.03 ng/mL; t = -3.635, p = 0.001) and cOCN (8.70 ± 2.27 vs. 10.77 ± 3.69 ng/mL; t = -2.30, p = 0.025) were lower in participants with T2DM. In participants without T2DM, concentrations of cOCN were associated with fitness (VO rho = 0.317, p = 0.047) and lower body fat (rho = -0.324, p = 0.041). In participants with T2DM, lower unOCN was associated with HbA1c (rho = -0.516, p = 0.020). Higher body mass was associated with higher unOCN (rho = 0.423, p = 0.009) in participants without T2DM, but with lower concentrations of both unOCN (rho = -0.590, p = 0.006) and cOCN (rho = -0.632, p = 0.003) in participants with T2DM.
In patients with CAD, lower osteocalcin concentrations were related to type 2 diabetes, and to adverse fitness, metabolic and obesity profiles.
成骨细胞衍生蛋白骨钙素的血清浓度较低与血糖控制不佳、胰岛素抵抗和动脉粥样硬化以及 2 型糖尿病（T2DM）的发生有关。
本研究比较了冠心病患者中 T2DM 患者（n=20）和年龄、性别和体重指数（BMI）匹配的无 T2DM 患者（n=40）的两种生理形式的骨钙素（羧化骨钙素[cOCN]和未羧化骨钙素[unOCN]）的浓度，并探讨了骨钙素浓度与心血管危险因素之间的关系。
T2DM 患者的 unOCN（2.71±1.86 与 4.70±2.03ng/mL；t=-3.635，p=0.001）和 cOCN（8.70±2.27 与 10.77±3.69ng/mL；t=-2.30，p=0.025）浓度较低。在无 T2DM 的患者中，cOCN 浓度与体能（VO rho=0.317，p=0.047）和体脂较低（rho=-0.324，p=0.041）相关。在 T2DM 患者中，较低的 unOCN 与 HbA1c 相关（rho=-0.516，p=0.020）。在无 T2DM 的患者中，较高的体重与较高的 unOCN 相关（rho=0.423，p=0.009），但与较低的 unOCN（rho=-0.590，p=0.006）和 cOCN（rho=-0.632，p=0.003）浓度相关。
在 CAD 患者中，较低的骨钙素浓度与 2 型糖尿病以及不良的体能、代谢和肥胖状况有关。
